IMNN

Imunon Inc

1.22

Oct 23 • 12:56 PM ET -0.03 (-2.40%)

Healthcare Biotechnology USA Nano NASD

Oct 21, 8:50 AMImunon to sell ThermoDox rights to VoxelDox Therapeutics for equity stake, milestones and royalties

Peers: GNPX AIM CLDI TOVX ONCY PDSB GNLX INO GOVX SLS

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	6.84M
Enterprise Value	7.83M
Income	-14.73M
Sales	0.00M
Book/sh	0.90
Cash/sh	1.22
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	20
IPO	Apr 04, 1994

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.36
P/C	1.00
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.82
Current Ratio	1.82
Debt/Eq	1.87
LT Debt/Eq	1.41
Option/Short	No / Yes

EPS (ttm)	-3.84
EPS next Y	-1.82
EPS next Q	-0.55
EPS this Y	65.42%
EPS next Y	22.95%
EPS next 5Y	41.53%
EPS past 3/5Y	52.95% 44.66%
Sales past 3/5Y	- -
EPS Y/Y TTM	71.67%
Sales Y/Y TTM	-
EPS Q/Q	71.00%
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	37.75% -

Insider Own	14.29%
Insider Trans	-2.71%
Inst Own	5.68%
Inst Trans	-6.58%
ROA	-123.77%
ROE	-429.72%
ROIC	-145.66%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	5.33%
SMA50	-11.54%
SMA200	-47.06%
Trades

Shs Outstand	5.61M
Shs Float	4.81M
Short Float	3.60%
Short Ratio	1.62
Short Interest	0.17M
52W High	5.03 -75.75%
52W Low	0.96 27.08%
Volatility	7.85% 8.56%
ATR (14)	0.10
RSI (14)	50.10
Beta	2.05
Rel Volume	0.23
Avg Volume	107.18K
Volume	13,839

Perf Week	19.61%
Perf Month	-9.63%
Perf Quarter	-20.26%
Perf Half Y	-56.27%
Perf YTD	-67.98%
Perf Year	-75.15%
Perf 3Y	-90.65%
Perf 5Y	-99.32%
Perf 10Y	-99.96%
Recom	1.00
Target Price	17.00
Prev Close	1.25
Price	1.22
Change %	-2.40%

Oct-21-26 08:15AM	IMUNON Announces Strategic Sale of ThermoDox (GlobeNewswire) +18.41%
Oct-08-26 09:00AM	IMUNON to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.14%
Sep-29-26 08:00AM	IMUNON Converts $1.2 Million of Debt-to-Equity (GlobeNewswire)
Sep-24-26 08:05AM	IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan (GlobeNewswire) -8.16%
Sep-22-26 08:05AM	IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review (GlobeNewswire) +5.59%
09:30AM	Loading…
Sep-10-26 09:30AM	IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 (GlobeNewswire)
Sep-09-26 08:30AM	IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress (GlobeNewswire)
Aug-26-26 08:30AM	IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001 (GlobeNewswire)
Aug-11-26 08:00AM	IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Aug-04-26 08:00AM	IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026 (GlobeNewswire) +5.70%
Jul-30-26 09:00AM	IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer (GlobeNewswire)
Jul-23-26 09:25AM	IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development (GlobeNewswire)
Jul-21-26 09:00AM	IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer (GlobeNewswire) -5.65%
Jun-23-26 08:00AM	IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification (GlobeNewswire)
Jun-22-26 04:15PM	IMUNON to Present at the Life Sciences Investor Forum on June 25th (GlobeNewswire)
10:32AM	Loading…
Jun-04-26 10:32AM	Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN) (InvestorsHub)
08:00AM	IMUNON Announces Up to $10 Million Cash Financing (GlobeNewswire)
May-12-26 07:00PM	Imunon Inc (IMNN) Q1 2026 Earnings Call Highlights: Promising Clinical Progress Amidst Funding ... (GuruFocus.com)
08:00AM	IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-05-26 08:30AM	IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026 (GlobeNewswire)
Mar-31-26 05:00PM	Imunon Inc (IMNN) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Management (GuruFocus.com)
08:00AM	IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study (GlobeNewswire)
Mar-25-26 08:05AM	IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer (GlobeNewswire) -5.44%
Mar-24-26 08:00AM	IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 (GlobeNewswire)
Feb-05-26 08:05AM	IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY (GlobeNewswire)
Dec-30-25 08:30AM	IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules (GlobeNewswire)
Dec-29-25 11:10AM	IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026 (GlobeNewswire) +15.24%
Nov-13-25 06:01PM	Imunon Inc (IMNN) Q3 2025 Earnings Call Highlights: Promising Advances in Immunotherapy and ... (GuruFocus.com) +5.32%
07:45AM	IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-10-25 01:30PM	IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer (GlobeNewswire) -6.25%
07:30AM	Loading…
07:30AM	IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer (GlobeNewswire)
Nov-07-25 08:05AM	IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment (GlobeNewswire)
Nov-06-25 08:05AM	IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025 (GlobeNewswire)
Nov-04-25 08:05AM	IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer (GlobeNewswire) -12.19%
Oct-30-25 08:00AM	IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting (GlobeNewswire)
Oct-23-25 10:01AM	IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting (GlobeNewswire)
Oct-20-25 08:05AM	IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer (GlobeNewswire)
Oct-17-25 08:10AM	IMUNON Invited to Present PlaCCine DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences (GlobeNewswire)
Oct-14-25 08:20AM	IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress (GlobeNewswire)
Sep-22-25 08:05AM	IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift (GlobeNewswire)
Sep-19-25 08:05AM	IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research (GlobeNewswire)
Sep-02-25 08:05AM	IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-28-25 08:05AM	IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement (GlobeNewswire)
Aug-06-25 03:20AM	Imunon Inc (IMNN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com) -6.22%
Aug-05-25 04:00PM	IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call (GlobeNewswire)
08:00AM	IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-30-25 08:05AM	IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer (GlobeNewswire)
Jul-29-25 08:30AM	IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025 (GlobeNewswire) +8.88%
Jul-28-25 08:05AM	IMUNON Announces Stock Dividend Boosting Shareholder Value (GlobeNewswire)
Jul-23-25 08:00AM	IMUNON Announces Reverse Stock Split (GlobeNewswire) -15.80%
Jul-17-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +22.30%
Jul-15-25 08:05AM	IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan (GlobeNewswire)
Jun-30-25 08:00AM	IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq's Listing Requirement, Anticipates Additional Compliance Period (GlobeNewswire) +8.11%
Jun-18-25 08:05AM	IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 (GlobeNewswire) -11.50%
Jun-17-25 08:05AM	IMUNON Announces PlaCCine DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development (GlobeNewswire)
Jun-13-25 08:35AM	Life Sciences Investor Forum: Now Available for Online Viewing (GlobeNewswire) -11.73%
Jun-10-25 02:38PM	Life Sciences Investor Forum Agenda Announced for June 11th-12th (GlobeNewswire) +21.80%
Jun-05-25 08:00AM	IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th (GlobeNewswire) -17.65%
Jun-04-25 07:41AM	ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer (Clinical Trials Arena) -10.99%
Jun-03-25 08:05AM	IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study (GlobeNewswire) -23.90%
Jun-02-25 08:05AM	IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS (GlobeNewswire)
May-28-25 11:55PM	Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More (Insider Monkey) -33.04% +30.92%
05:16PM	IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
May-27-25 08:20AM	Imunon announces up to $9.75M private placement priced at-the-market (TipRanks) +95.69%
08:05AM	IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 (GlobeNewswire)
May-23-25 06:59PM	IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +179.18%
08:05AM	IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer (GlobeNewswire)
May-22-25 05:20PM	IMUNON Announces Withdrawal of Form S-1 Registration Statement (GlobeNewswire)
May-15-25 08:05AM	IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19 (GlobeNewswire) -8.37%
May-13-25 03:07AM	Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
01:59AM	Q1 2025 Imunon Inc Earnings Call (Thomson Reuters StreetEvents)
May-12-25 08:00AM	IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-08-25 08:05AM	IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer (GlobeNewswire)
May-06-25 08:05AM	IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology (GlobeNewswire)
May-05-25 08:00AM	IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025 (GlobeNewswire)
Apr-21-25 08:05AM	IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting (GlobeNewswire)
Mar-25-25 06:48AM	FDA aligns with Imunons Phase III trial protocol for ovarian cancer treatment (Clinical Trials Arena) -6.11%
Mar-24-25 08:00AM	IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer (GlobeNewswire) +12.11%
Feb-28-25 04:29AM	Q4 2024 Imunon Inc Earnings Call (Thomson Reuters StreetEvents) +9.96%
02:28AM	Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges (GuruFocus.com)
Feb-27-25 08:05AM	IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study (GlobeNewswire)
07:36AM	Imunon reports immunogenicity and safety data from DNA plasmid vaccine trial (Clinical Trials Arena)
Feb-26-25 08:05AM	IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19 (GlobeNewswire)
Feb-20-25 08:30AM	IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 (GlobeNewswire)
Feb-19-25 08:05AM	IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer (GlobeNewswire)
Feb-10-25 08:05AM	IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Dec-19-24 08:05AM	IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer (GlobeNewswire)
Dec-10-24 08:05AM	IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001 (GlobeNewswire)
Nov-25-24 08:05AM	IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer (GlobeNewswire)
Nov-08-24 02:23AM	Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ... (GuruFocus.com)
Nov-07-24 10:00AM	IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting (GlobeNewswire) -12.34%
08:05AM	IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-31-24 08:30AM	IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024 (GlobeNewswire)
Oct-30-24 09:05AM	IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting (GlobeNewswire)
Oct-08-24 08:45AM	Imunon reports inducement grant under NASDAQ listing rule (TipRanks)
Oct-07-24 08:05AM	IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.56%
Sep-09-24 04:06PM	UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management (GlobeNewswire)
08:30AM	IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Eylward Susan	General Counsel and Corp Sec	Aug 31 '26	Sale	1.56	2,525	3,950	2,896	Sep 01 04:06 PM
Eylward Susan	General Counsel and Corp Sec	Aug 17 '26	Sale	1.63	2,449	3,993	2,896	Aug 17 04:17 PM
Eylward Susan	General Counsel and Corp Sec	Aug 03 '26	Sale	1.57	2,541	3,977	2,896	Aug 04 04:13 PM
Eylward Susan	General Counsel and Corp Sec	Jul 20 '26	Sale	1.78	2,150	3,830	2,896	Jul 21 04:15 PM
Eylward Susan	General Counsel and Corp Sec	Jul 06 '26	Sale	1.88	920	1,730	2,896	Jul 07 04:58 PM
Eylward Susan	General Counsel and Corp Sec	Jun 29 '26	Sale	1.75	11,800	20,674	2,896	Jun 29 04:34 PM

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Executive ChairmanMr. Michael H. Tardugno

PresidentDr. Stacy R. Lindborg Ph.D.

Ph.D.Dr. Douglas V. Faller M.D.

M.B.A.Mr. Joshua Blacher CPA

Senior Vice President of Strategic OperationsMs. Kristin Longobardi M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMNN

Imunon Inc

Upgrade your Finviz experience